Skip to main content

Fujifilm Unveils the XF500mmF5.6 R LM OIS WR: A Super-Telephoto Lens Redefining Mobility and Accessibility

SHERIDAN, WYOMING – November 9, 2024 – FUJIFILM Corporation is thrilled to announce the global launch of the FUJINON Lens XF500mmF5.6 R LM OIS WR (XF500mmF5.6 R LM OIS WR), a groundbreaking addition to the esteemed XF lens lineup for the X Series mirrorless digital cameras.  This lens redefines the boundaries of super-telephoto photography, offering exceptional optical performance in a remarkably compact and lightweight design.    

"The XF500mmF5.6 R LM OIS WR is a testament to Fujifilm's unwavering commitment to innovation and pushing the boundaries of optical engineering," said a spokesperson for FUJIFILM Corporation. "This lens empowers photographers of all levels of expertise to capture stunning images in the super-telephoto range with unparalleled ease and precision."

Unleashing the Power of Super-Telephoto Photography

Fujifilm Unveils the FUJINON XF16-55mmF2.8 R LM WR II Lens: A Lightweight Powerhouse for Superior Image Quality

SHERIDAN, WYOMING – November 9, 2024 – Fujifilm has announced the launch of the FUJINON XF16-55mmF2.8 R LM WR II lens, a new addition to their X Series of interchangeable lenses.  This lens is designed to provide outstanding image quality in a compact and lightweight body.    

The XF16-55mmF2.8 R LM WR II is the successor to the XF16-55mmF2.8 R LM WR, a large-aperture standard zoom lens and flagship model in the XF lens series.  It is 37% lighter than its predecessor, making it an ideal choice for photographers who need a versatile lens that is easy to carry.    

The lens configuration has been optimized to enhance descriptive performance.  It features an "Aperture Click Switch," a first for the XF lens series, that allows users to choose between a click and de-click setting when operating the aperture ring.  The de-click setting enables smooth brightness changes, which is particularly useful for videographers.    

FUJIFILM Unveils the X-M5: A Compact Powerhouse for Photography Enthusiasts

SHERIDAN, WYOMING – November 9, 2024 – FUJIFILM Corporation is thrilled to announce the launch of the FUJIFILM X-M5, a cutting-edge mirrorless digital camera that redefines the balance between portability and performance. The X-M5, available from mid-November 2024, is the lightest model in the acclaimed X Series, offering exceptional image quality in a compact and lightweight design.    
Weighing approximately 355g, the X-M5 is designed for photographers on the move. It's packed with advanced features, including subject-detection autofocus that leverages AI to track moving subjects like animals and vehicles, and a 6.2K/30P movie recording function for capturing stunning video footage.    

Fujifilm Launches Innovative EUV Resist and Developer

SHERIDAN, WYOMING – November 9, 2024 – Enhancing EUV Lithography Materials Production in Japan and South Korea
In a move set to revolutionize semiconductor manufacturing, FUJIFILM Corporation has announced the launch of its cutting-edge negative-tone resists and developer for EUV lithography. This technology is poised to become the cornerstone of advanced semiconductor manufacturing processes, paving the way for smaller, more powerful chips.    

Fujifilm has earned its stripes in the industry as the pioneer behind the world's first NTI process, a negative development process that has been instrumental in miniaturizing semiconductor circuits using ArF lithography. With the introduction of its negative-tone EUV resist and EUV developer, Fujifilm continues to push the boundaries of miniaturization, optimizing circuit pattern formation for the next generation of semiconductors.    

FUJIFILM Holdings' Chairman Kenji Sukeno Awarded Japan's Order of the Rising Sun, Gold and Silver Star

SHERIDAN, WYOMING – November 9, 2024 – FUJIFILM Holdings Corporation is pleased to announce that Kenji Sukeno, Chairman, Director & Board Chairman, has been awarded the prestigious Order of the Rising Sun, Gold and Silver Star. This distinguished honor, bestowed by the Japanese government, recognizes individuals who have made significant contributions to the nation and the public good.    
Mr. Sukeno's leadership has been instrumental in FUJIFILM's successful transformation. Despite the challenges posed by digitalization, he has guided the company to strategically invest in the healthcare sector, strengthening its foundation for future growth.    

FUJIFILM Diosynth Biotechnologies Takes a Major Step Forward in Global Expansion

SHERIDAN, WYOMING – November 9, 2024 – FUJIFILM Diosynth Biotechnologies, a leading Contract Development and Manufacturing Organization (CDMO) specializing in biologics, vaccines, advanced therapies, and oncolytic viruses, has announced the completion of the first phase of its expansion project at its Hillerød, Denmark site.  This achievement is a significant milestone in the company's plan to establish a global network of facilities dedicated to improving the manufacturing and delivery of life-saving medications.    

The first phase of the expansion project has resulted in the addition of six mammalian cell bioreactors, increasing the total capacity at the Hillerød site to an impressive 12 x 20,000 L bioreactors.  The next phase, backed by a substantial capital investment, will see the addition of 8 x 20,000 L bioreactors and two downstream processing streams.    

Fujifilm Announces Robust Financial Results for the First Half of Fiscal Year 2024

SHERIDAN, WYOMING – November 9, 2024 – Company Maintains Positive Outlook for the Remainder of the Fiscal Year
FUJIFILM Holdings Corporation today announced strong financial results for the first half of the fiscal year ending March 31, 2025. The company reported a 9.1% year-over-year increase in revenue, reaching JPY1,514.7 billion. This growth was primarily fueled by strong sales in the Electronics and Imaging businesses, along with favorable foreign exchange rates.    
Operating income also demonstrated a healthy increase of 8.0% year-over-year, reaching JPY135.6 billion. The company attributed this growth to the increase in revenue and the positive impact of exchange rates.    
Despite a slight decrease in net income attributable to FUJIFILM Holdings, which was down 2.9% year-over-year to JPY110.3 billion, the company remains optimistic about its future prospects.    

Varian Medical Systems: Pioneering the Fight Against Cancer with TrueBeam Radiotherapy System

SHERIDAN, WYOMING – November 9, 2024 – Varian Medical Systems, a Siemens Healthineers company, is proud to showcase its innovative TrueBeam® radiotherapy system, a cutting-edge technology designed to revolutionize cancer treatment. TrueBeam integrates hardware, software, treatment regimens, and safety features to provide clinicians with the tools they need to deliver precise and effective radiation therapy.    

"Advances in radiation therapy are accelerating, creating new options for treatment and new sources of optimism in the fight against cancer," says Varian Medical Systems.    

TrueBeam's comprehensive capabilities enable clinicians to focus on patients and treatments rather than systems and technologies. The system's integrated imaging system allows for improved soft tissue target visualization and faster cone-beam CT (CBCT) acquisitions, facilitating breath-hold treatments.

Terumo Corporation Announces Executive Leadership Transition

SHERIDAN, WYOMING – November 9, 2024 – Terumo Corporation (TSE: 4543) today announced a series of strategic leadership appointments to further strengthen its global operations and drive continued innovation in medical technology. The changes, effective October 1, 2024, included key positions within the Cardiac and Vascular Company and Terumo Americas Holding, Inc.

New Leadership Appointments

Fumihisa Hirose was promoted to Group Managing Executive Officer and President of the Cardiac and Vascular Company.  Mr. Hirose previously served as President of the Cardiac and Vascular Company and Division President of the Interventional Systems Division.

Ghada Farah was appointed as Division President of the Interventional Systems Division within the Cardiac and Vascular Company. Ms. Farah brought extensive experience to this role, having previously served as Senior Vice President for EMEA in the Interventional Systems Division at Terumo Europe N.V.

Terumo Blood and Cell Technologies Revolutionizes U.S. Blood Processing with Launch of Reveos System

SHERIDAN, WYOMING – November 9, 2024 – In a move set to transform blood processing in the United States, Terumo Blood and Cell Technologies (Terumo BCT) has launched the Reveos™ Automated Blood Processing System.  This innovative technology, already used in over 50 countries for more than a decade, promises to significantly enhance efficiency and address critical platelet shortages.

"Reveos is a revolutionary technology that automates whole blood processing. By streamlining the process, it significantly improves efficiency and consistency compared to traditional manual methods used by U.S. blood centers," says Chetan Makam, General Manager, Global Blood Solutions, Terumo BCT. "It's a new way to be more efficient for blood centers, for processing whole blood into its components including platelets. Reveos will help blood centers do more with the blood donors already walking through the doors."